Back to top
more

ADMA Biologics (ADMA)

(Delayed Data from NSDQ)

$19.98 USD

19.98
45,181,425

+0.24 (1.22%)

Updated Sep 20, 2024 04:00 PM ET

After-Market: $20.09 +0.11 (0.55%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (79 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Adma Biologics (ADMA) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the closing of the recent trading day, Adma Biologics (ADMA) stood at $19.98, denoting a +1.22% change from the preceding trading day.

Ekta Bagri headshot

ADMA Biologics Stock Soars 76.2% in 3 Months: Right Time to Invest?

by Ekta Bagri

ADMA stock surges 76.2% in three months on strong performance and high growth prospects. It recently hit its 52-week high with more room for growth.

Is First Trust Small Cap Growth AlphaDEX ETF (FYC) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FYC

Is Assembly Biosciences (ASMB) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Assembly Biosciences (ASMB) and Adma Biologics (ADMA) have performed compared to their sector so far this year.

Here's Why Momentum in Adma Biologics (ADMA) Should Keep going

by Zacks Equity Research

If you are looking for stocks that are well positioned to maintain their recent uptrend, Adma Biologics (ADMA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Should First Trust Small Cap Growth AlphaDEX ETF (FYC) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for FYC

Adma Biologics (ADMA) Recently Broke Out Above the 20-Day Moving Average

by Zacks Equity Research

Is it a good or bad thing when a stock surpasses resistance at the 20-day simple moving average?

ADMA Biologics Inc (ADMA) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

Adma Biologics (ADMA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Should First Trust Small Cap Core AlphaDEX ETF (FYX) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for FYX

Abhinab Dasgupta headshot

Beat the Market Like Zacks: CareDx, Fair Isaac, 3M in Focus

by Abhinab Dasgupta

Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.

Is ADMA Biologics (ADMA) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Adma Biologics (ADMA) and CareDx (CDNA) have performed compared to their sector so far this year.

Is Adma Biologics (ADMA) a Buy as Wall Street Analysts Look Optimistic?

by Zacks Equity Research

The average brokerage recommendation (ABR) for Adma Biologics (ADMA) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

Here's What Could Help Adma Biologics (ADMA) Maintain Its Recent Price Strength

by Zacks Equity Research

Adma Biologics (ADMA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Is First Trust Small Cap Core AlphaDEX ETF (FYX) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FYX

Ekta Bagri headshot

ADMA Biologics (ADMA) Hits 52-Week High: More Room to Grow?

by Ekta Bagri

The ADMA Biologics (ADMA) stock surges in a month on impressive second-quarter results. It has recently hit its 52-week high with more room for growth.

Is Perspective Therapeutics, Inc. (CATX) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Perspective Therapeutics (CATX) and Adma Biologics (ADMA) have performed compared to their sector so far this year.

Brokers Suggest Investing in Adma Biologics (ADMA): Read This Before Placing a Bet

by Zacks Equity Research

According to the average brokerage recommendation (ABR), one should invest in Adma Biologics (ADMA). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

ADMA Biologics Inc (ADMA) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

Adma Biologics (ADMA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Adma Biologics (ADMA) is on the Move, Here's Why the Trend Could be Sustainable

by Zacks Equity Research

If you are looking for stocks that are well positioned to maintain their recent uptrend, Adma Biologics (ADMA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Adma Biologics (ADMA) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Adma Biologics (ADMA) delivered earnings and revenue surprises of 62.50% and 23.17%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Sangamo Therapeutics (SGMO) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Sangamo (SGMO) delivered earnings and revenue surprises of -6.25% and 96.88%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Vertex (VRTX) Q2 Loss Wider Than Expected, '24 Sales View Raised

by Zacks Equity Research

Vertex (VRTX) incurs a wider-than-expected loss in the second quarter while sales come in line with estimates. Vertex raises its full-year product revenue guidance.

Nilanjan Banerjee headshot

Navigate Market Turbulence With These 4 Low-Beta Stocks

by Nilanjan Banerjee

It is imperative to build a portfolio of low-beta stocks to sail through a volatile market. Erie Indemnity (ERIE), TreeHouse (THS), HII (HII) and ADMA Biologics (ADMA) are well-poised to gain.

Adma Biologics (ADMA) Rises But Trails Market: What Investors Should Know

by Zacks Equity Research

In the latest trading session, Adma Biologics (ADMA) closed at $12.28, marking a +0.82% move from the previous day.

Adma Biologics (ADMA) Suffers a Larger Drop Than the General Market: Key Insights

by Zacks Equity Research

In the latest trading session, Adma Biologics (ADMA) closed at $12.18, marking a -1.46% move from the previous day.